Stock Track | Organon & Co Soars 14.92% in Pre-market on $11.75 Billion Acquisition by Sun Pharma

Stock Track
Apr 27

Organon & Co's stock surged 14.92% in pre-market trading following the announcement of a definitive agreement to be acquired by Sun Pharmaceutical Industries.

The sharp rise was driven by news that Sun Pharma will acquire Organon in an all-cash transaction valued at approximately $11.75 billion. Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, representing a significant premium to recent trading prices.

The acquisition is expected to enhance Sun Pharma's global footprint, particularly in women's health and biosimilars, while creating a combined entity with projected revenues of about $12.4 billion. The transaction has been approved by the boards of both companies and is anticipated to close in early 2027, subject to regulatory approvals and Organon stockholder consent.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10